The estimated Net Worth of Jon Kuwahara is at least $489 Mille dollars as of 20 May 2019. Mr. Kuwahara owns over 5,276 units of Novus Therapeutics Inc stock worth over $87,220 and over the last 7 years he sold NVUS stock worth over $10,288. In addition, he makes $391,401 as Chief Financial Officer e Chief Accounting Officer at Novus Therapeutics Inc.
Jon has made over 1 trades of the Novus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,276 units of NVUS stock worth $10,288 on 20 May 2019.
The largest trade he's ever made was selling 5,276 units of Novus Therapeutics Inc stock on 20 May 2019 worth over $10,288. On average, Jon trades about 754 units every 0 days since 2017. As of 20 May 2019 he still owns at least 5,974 units of Novus Therapeutics Inc stock.
You can see the complete history of Mr. Kuwahara stock trades at the bottom of the page.
Jon S. Kuwahara CPA serves as Chief Financial Officer, Chief Accounting Officer of the Company. He has over 25 years of finance and operations experience, primarily within the pharmaceutical industry. In his previous roles, Mr. Kuwahara directed all aspects of finance and accounting operations, including financial reporting, internal controls, treasury management, and budgeting. Prior to joining the Company, from June 2016 to June 2017, Mr. Kuwahara served as Vice President of Finance at Espero Pharmaceuticals, a private pharmaceutical company focused on the development and commercialization of cardiovascular products. Prior to Espero, from November 2014 to June 2016, Mr. Kuwahara served in multiple roles, most recently as Corporate Controller, at Avanir Pharmaceuticals. Prior to Avanir, from October 2010 to October 2014, Mr. Kuwahara served as Assistant Corporate Controller at Questcor Pharmaceuticals, a public specialty pharmaceutical company (acquired by Mallinckrodt Pharmaceuticals). From December 2015 until September 2018, Mr. Kuwahara served as a member of the Board of Directors, and Chairman of the Audit Committee, for Emmaus Life Sciences, Inc., a biopharmaceutical company focused on rare and orphan diseases. Mr. Kuwahara holds a B.B.A. with emphasis in accounting from the University of Hawaii and is a certified public accountant in California and Hawaii.
As the Chief Financial Officer e Chief Accounting Officer of Novus Therapeutics Inc, the total compensation of Jon Kuwahara at Novus Therapeutics Inc is $391,401. There are 1 executives at Novus Therapeutics Inc getting paid more, with John McBride having the highest compensation of $647,278.
Jon Kuwahara is 54, he's been the Chief Financial Officer e Chief Accounting Officer of Novus Therapeutics Inc since 2020. There are 3 older and 2 younger executives at Novus Therapeutics Inc. The oldest executive at Novus Therapeutics Inc is Gary Lyons, 68, who is the Independent Director.
Jon's mailing address filed with the SEC is C/O NOVUS THERAPEUTICS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE, CA, 92612.
Over the last 7 years, insiders at Novus Therapeutics Inc have traded over $2,287,089 worth of Novus Therapeutics Inc stock and bought 1,499,013 units worth $7,312,148 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Israel Gp Ltd.Orbi Med Isra... e Erez Chimovits. On average, Novus Therapeutics Inc executives and independent directors trade stock every 100 days with the average trade being worth of $1,832,709. The most recent stock trade was executed by Israel Gp Ltd.Orbi Med Isra... on 2 December 2020, trading 103,200 units of NVUS stock currently worth $2,229,120.
Novus Therapeutics Inc executives and other stock owners filed with the SEC include: